On December 15, 2021, BeiGene, Ltd. was successfully listed on the SSE STAR Market. 115,055,260 shares were listed at an issuance price of RMB 192.60 per share, raising approximately RMB 22.2 billion. These funds are to be used for clinical trial research and development, marketing, construction projects, manufacturing research, development, marketing and industrialization projects, as well as supplementing working capital.